The journey of Sotagliflozin: from its status as a withdrawn candidate for the treatment of diabetes mellitus, to its repurposing as a groundbreaking drug for the management of heart failure

Pharmacy Practice

  • Dania A. Hussein1Assistant Professor, Department of Pharmacology, College of Pharmacy, Imam Abdulrahman Bin Faisal University, King Faisal Road, Eastern Province, Dammam, P.O. Box 1982, Dammam 31441, Saudi Arabia.

Volume 23 Issue 3 Pages 1-10

DOI: 10.18549/PharmPract.2025.3.3265

Abstract

Sotagloflozin is a member of the antidiabetic class of sodium-dependent glucose cotransporter protein inhibitors. It is unique in its class due to its dual inhibitory action, as it can target and inhibit both type 1 and type 2 isoforms of the sodium glucose co-transporter (SGLT). SGLT inhibitors are small-molecule antagonists whose design was inspired by the natural product phlorizin. In May 2023, the United States Food and Drug Administration (U.S. FDA) approved sotagliflozin for the treatment of heart failure. The journey towards the discovery and optimization of this compound, as well as its ultimate repurposing in the setting of heart failure, is intriguing and continues to arouse interest and concern with regard to the safety and applicability of this repositioned candidate. This review offers an in-depth critical report of the journey of this compound, which has been marked by moments of both success and failure, towards its ultimate reproposing and a reported groundbreaking role in the scope of heart failure management.

Keywords

  • Sotagliflozin
  • SGLT-Inhibitors Drug Repurposing
  • Heart Failure
  • Diabetes
Pharmacy Practice

Loading…